Rendering
Component: (Network and Table) |
---|
Network | 2313301 - Disclosure - Income Taxes (Tables) (http://www.acceleronpharma.com/role/IncomeTaxesTables) |
Table | (Implied) |
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis] | 0001280600 (http://www.sec.gov/CIK) |
Income Tax Disclosure [Abstract] | Period [Axis] |
---|
2016-01-01 - 2016-12-31 |
---|
Income Tax Disclosure [Abstract] | |
Components of the Company's Deferred Tax Assets | The significant components of the Company's deferred tax assets are comprised of the following (in thousands): | | | | | | | | | | Year Ended December 31, | | 2016 | | 2015 | Deferred tax assets: | | | |
| U.S. and state net operating loss carryforwards | $ | 109,429 |
| | $ | 90,732 |
| Research and development credits | 9,717 |
| | 7,864 |
| Deferred revenue | 1,666 |
| | 1,883 |
| Accruals and other temporary differences | 15,725 |
| | 9,319 |
| Total deferred tax assets | 136,537 |
| | 109,798 |
| Less valuation allowance | (136,537 | ) | | (109,798 | ) | Net deferred tax assets | $ | — |
| | $ | — |
|
|
Schedule of Effective Income Tax Rate Reconciliation | A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the consolidated financial statements is as follows: | | | | | | | | | | | Year Ended December 31, | | 2016 | | 2015 | | 2014 | Federal income tax expense at statutory rate | 34.0 | % | | 34.0 | % | | 34.0 | % | State income tax, net of federal benefit | 5.9 | % | | 4.6 | % | | 4.1 | % | Permanent differences | 4.0 | % | | (8.3 | )% | | 2.0 | % | Research and development credit | 3.1 | % | | 1.2 | % | | 1.6 | % | Other | (0.1 | )% | | — | % | | 4.6 | % | Change in valuation allowance | (46.9 | )% | | (31.5 | )% | | (46.3 | )% | Effective income tax rate | — | % | | — | % | | — | % |
|